Showing 801 - 820 results of 9,330 for search 'significantly ((((((less decrease) OR (teer decrease))) OR (mean decrease))) OR (we decrease))', query time: 0.63s Refine Results
  1. 801
  2. 802
  3. 803
  4. 804
  5. 805

    Flow chart of experimental protocol. by Eun-Seon Yang (19751340)

    Published 2024
    “…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”
  6. 806

    A representative ultrasound axis image. by Eun-Seon Yang (19751340)

    Published 2024
    “…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”
  7. 807
  8. 808
  9. 809
  10. 810
  11. 811
  12. 812
  13. 813

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  14. 814

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  15. 815

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  16. 816
  17. 817

    Demethylation Pathway of Methylmercury in the Spleen and Peripheral Organs of Bluefin TunaImplications for Fish Consumers by Alain Manceau (1455781)

    Published 2025
    “…While the spleen is well-known as the body’s largest immune organ, its role in detoxification is less recognized. Here, we used high-energy-resolution X-ray absorption spectroscopy to examine the chemical forms of mercury (Hg) in ABFT tissues, building on prior analysis of stable Hg isotopes. …”
  18. 818
  19. 819
  20. 820